Anti-Sars-CoV-2 vaccination campaign in children aged 5-11 years: the experience of a mass vaccination center in the city of Milan

Main Article Content

Elisa Astorri
Francesco Mazziotta
Claudio Macrelli
Navpreet Tiwana
Matteo Letzgus
Alberto Bisesti
Dario Laquintana
Laura Chiappa
Alessandra Piatti
Marcello Sottocorno
Francesco Falbo
Matilde Rosso
Ludovica Caprini
Silvana Castaldi

Keywords

pediatric vaccination center, Sars-CoV-2 pediatric vaccines, pediatric vaccines, mass vaccination center, vaccination center organization

Abstract

Background and aim: After the approval of the anti-Sars-CoV-2 vaccines for the pediatric population, it is necessary to encourage the immunization of children aged 5-11 years, as this can reduce intergenerational transmission. Therefore, this goal has become a priority for the COVID 19 vaccination campaign in Italy. In the city of Milan, the mass vaccination center (MVC) Fiera Milano City, previously settled for general population, became the main site to host pediatric vaccinations. The center was consequently remodeled to ensure a suitable space for children. This paper provides an overview on the organization strategy implemented by Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico. The modular structure and the wide surface available in the center allowed the administration of hundreds of vaccines per day, especially in the first opening phase.


Methods: All the data for the entire period of activity of Fiera MCV, from December 16th 2021 to February 20th 2022, were analyzed using descriptive statistics.


Results: During the entire period of activity, from 16 December 2021 to 20 February 2022, 23% of the population in the province of Milan aged 5-11 years has been reached and vaccinated with at least one shot of vaccine in this center.


Conclusions: Despite an enthusiastic response in the first weeks of the campaign, a progressive reduction in vaccination adherence was observed, maybe due to the absence of restrictive measures for unvaccinated children in Italy.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...
Abstract 280 | PDF Downloads 189

References

1. WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19. 11 March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
2. WHO. Interim statement on COVID-19 vaccination for children and adolescents. 24 November 2021. https://www.who.int/news/item/24-11-2021-interim-statement-on-covid-19-vaccination-for-children-and-adolescents
3. Istituto Superiore di Sanità. Epidemia COVID-19. Aggiornamento nazionale 12 gennaio 2022. https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_12-gennaio-2022
4. Lu X, Zhang L, Du H et al. SARS-CoV-2 Infection in Children. New England Journal of Medicine, vol. 382, no. 17, pp. 1663–1665, Mar. 2020, doi: 10.1056/NEJMc2005073.
5. Götzinger F, Santiago-García B, Noguera-Julián A et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. The Lancet Child and Adolescent Health, vol. 4, no. 9, pp. 653–661, 2020, doi: 10.1016/S2352-4642(20)30177-2.
6. Tsankov BK, Allaire JM, Irvine MA et al. Severe COVID-19 Infection and Pediatric Comorbidities: A Systematic Review and Meta-Analysis. International Journal of Infectious Diseases, vol. 103, no. January, pp. 246–256, 2021, doi: 10.1016/j.ijid.2020.11.163.
7. Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. The Lancet Infectious Diseases, vol. 20, no. 11, pp. e276–e288, 2020, doi: 10.1016/S1473-3099(20)30651-4.
8. Buonsenso D, Munblit D, De Rose C et al. Preliminary evidence on long COVID in children. Acta Paediatrica, International Journal of Paediatrics, vol. 110, no. 7, pp. 2208–2211, 2021, doi: 10.1111/apa.15870.
9. EMA. Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11. https://www.ema.europa.eu/en/news/comirnaty-covid-19-vaccine-ema-recommends-approval-children-aged-5-11
10. FDA. FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children through 11 Years of Age. https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age
11. Walter EB, Talaat KR, Sabharwal C et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. New England Journal of Medicine, vol. 386, no. 1, pp. 35–46, Nov. 2021. doi: 10.1056/NEJMoa2116298.
12. AIFA. AIFA approva il vaccino Comirnaty per la fascia di età 5-11 anni. https://www.aifa.gov.it/documents/20142/1289678/Comunicato_AIFA_674
13. Ministero della Salute, presidenza del Consiglio dei Ministri, Commissario Straordinario COVID-19. Report Vaccini Anti COVID-19. https://www.governo.it/it/cscovid19/report-vaccini/
14. Regione Lombardia, deliberazione n° XI / 4353. Approvazione del piano regionale vaccini per la prevenzione delle infezioni da Sars-CoV-2. Seduta del 24/02/2021.
15. Oliani F, Savoia A, Gallo G et al. Italy's rollout of COVID-19 vaccinations: The crucial contribution of the first experimental mass vaccination site in Lombardy. Vaccine. 2022 Feb 3:S0264-410X(22)00115-3. doi: 10.1016/j.vaccine.2022.01.059. Epub ahead of print. PMID: 35144846; PMCID: PMC8810348.
16. Istituto Superiore di Sanità. Vaccini COVID-19. https://www.iss.it/vaccini-covid-19

Most read articles by the same author(s)

1 2 3 > >> 

Similar Articles

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 > >> 

You may also start an advanced similarity search for this article.